Ardelyx appoints Sue Hohenleitner as chief financial officer effective November 4

Ardelyx, Inc. (NASDAQ:ARDX) announced the appointment of Sue Hohenleitner as chief financial officer and principal financial officer, effective November 4, 2025. The decision was made by the board of directors on Monday, according to a statement based on the company’s SEC filing.

Ms. Hohenleitner, age 55, joins Ardelyx after serving in senior finance roles at Johnson & Johnson, most recently as vice president and chief financial officer of Johnson & Johnson Innovative Medicine North America since August 2022. Her prior positions at Johnson & Johnson included vice president of finance at J&J Innovation, vice president of finance for acquisition and divestiture operations, and vice president of finance for J&J Supply Chain Deliver.

Ms. Hohenleitner holds a Bachelor of Science in Accounting from La Salle University and an MBA from Villanova. She is a Certified Public Accountant in Pennsylvania and a Certified Management Accountant.

Under the terms of her offer letter, Ms. Hohenleitner will receive an annual base salary of $550,000 and a target annual bonus opportunity of 45% of her base salary, subject to the achievement of goals set by the board. For 2025, the bonus will be pro-rated based on her period of service during the year. With analyst price targets ranging from $8 to $15 per share and a consensus "Strong Buy" recommendation, InvestingPro analysis suggests the stock is currently trading below its Fair Value, presenting a potential opportunity for investors seeking undervalued healthcare stocks.

In connection with her appointment, Ms. Hohenleitner received a sign-on bonus of $180,000 and a housing consideration payment of $150,000. She was also granted an option to purchase 578,104 shares of Ardelyx common stock at an exercise price of $5.01 per share, the closing price on the grant date. The options will vest 25% on the first anniversary of her start date, with the remainder vesting monthly over the following three years. Additionally, she received 146,896 restricted stock units, vesting 25% after one year and the remainder quarterly over the next three years.

The company intends to enter into standard indemnification and change in control severance agreements with Ms. Hohenleitner. Ardelyx stated there are no family relationships or related party transactions between Ms. Hohenleitner and company directors or officers. This information is based on a press release statement filed with the SEC. For a comprehensive analysis of Ardelyx’s financial health, valuation metrics, and growth prospects, investors can access the detailed Pro Research Report available exclusively on InvestingPro, which covers over 1,400 US stocks with expert insights and actionable intelligence.

In other recent news, Ardelyx Inc. reported its second-quarter 2025 earnings, showcasing a significant earnings surprise. The company announced a net loss of $0.08 per share, outperforming analysts’ expectations of a $0.13 loss. Revenue for the quarter reached $97.7 million, surpassing the forecast of $82.51 million, marking an 18.41% surprise. Raymond James responded to these strong sales by raising its price target for Ardelyx to $12.00 from $11.00, while maintaining an Outperform rating. Additionally, Raymond James reiterated its Strong Buy rating and a $14.00 price target after a court hearing related to Ardelyx’s legal challenge against the Centers for Medicare & Medicaid Services. In another development, Ardelyx appointed Sue Hohenleitner as its new Chief Financial Officer. Hohenleitner joins Ardelyx with over 30 years of experience, including a 28-year tenure at Johnson & Johnson. These developments highlight Ardelyx’s ongoing efforts to strengthen its leadership and financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.